UpToDate® : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
The American Society of Clinical Oncology elected Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, to lead as its President beginning in June 2026. Dr. Mittendorf,…
Over 800 million people have genital herpes — and in many cases the virus can flare up over a person’s lifetime, causing painful symptoms. So…
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
The ASH Congressional Fellowship aims to provide education about the policymaking process, including Congress’ relationship to the hematology community, as well as an opportunity to…
Nature Reviews Cancer – Patient-derived xenograft (PDX) models are valuable surrogates for drug testing in precision oncology. In this Review, Welm and colleagues outline the…
Key PointsNo difference in the cumulative incidence of bleeding in ET patients with vs without ExT.There is no clear indication for cytoreduction to decrea
Icro Meattini, MD, University of Florence, Florence, Italy, discusses the interim findings of the Phase III EUROPA trial (NCT04134598), which compared radiotherapy and endocrine therapy…
Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel therapies.
Welcome to ASTRO President’s Corner, a new video series where ASTRO President, Sameer Keole, MD, FASTRO, and other ASTRO leadership, will present different topics and…
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.